ClinicalTrials.gg
CompletedNCT06336629Updated Jul 17, 2025Results posted

A Study Assessing the Efficacy and Safety of Combined Use of Clascoterone 1% Cream and Duac Gel (Benzoyl Peroxide/Clindamycin) for the Treatment of Acne

A Phase 4 interventional study of Winlevi (clascoterone) 1% & Duac gel in Acne Vulgaris, sponsored by Sun Pharmaceutical Industries Limited. Completed at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-07-17.

Sponsored by Sun Pharmaceutical Industries Limited · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Nov 2023, registered Mar 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies testing clascoterone in Acne Vulgaris — 5 open to participants now, 7 under way, 2 of them phase 3. Clascoterone · Acne Vulgaris.

Enrollment
17th of 19
10 · median 50
Started
2023
with 3 others
Phase 4
7 of 19
1 open now
Registered
8th of 19
by date
Lead sponsor
6 of 19
Sun Pharmaceutical Industries Limited

Among the 19 studies testing clascoterone in Acne Vulgaris, this one is the 17th largest by enrollment, is one of 4 that started in 2023, is one of 7 in phase 4, and was the 8th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 94 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

5 of the 19 studies testing clascoterone in Acne Vulgaris are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About clascoterone

Clascoterone: first FDA approval 2020 (WINLEVI), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 47 Acne Vulgaris studies recruiting now, 17 (36%) set no upper age limit and 29 (62%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing clascoterone in Acne Vulgaris, or all of them as a file.
02

Study summary

Winlevi is the first topical anti androgen and sebum inhibitor approved for acne vulgaris. There is no study assessing Winlevi in combination treatment for acne .Therefore this study assesses Winlevi with Duac gel in combination to emulate real life practice.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

i. Outpatient, male or female subjects of any race, and at least 12 years of age or older.

  • Female subjects of must have a negative urine pregnancy test result at Baseline (test must have a sensitivity of at least 25mIU/ml for human chorionic gonadotropin) and practice a reliable method of throughout the study:
  • A female is considered of childbearing potential unless she is:

    1. for at least 12 months prior to study drug administration;
    2. without a uterus and/or both ovaries; or
    3. Has been surgically sterile for at least 6 months prior to study drug administration.
  • Reliable methods of contraception are:

    1. Hormonal methods or intrauterine device in use > 90 days prior to study drug administration;
    2. Barrier methods plus spermicide in use at least 14 days prior to study drug administration; or
    3. Vasectomized partner (vasectomy must be performed 3 months prior to first study drug administration or in the alternative a zero sperm count will suffice).
  • Exception: Female subjects of childbearing potential who are not sexually active will not be required to practice a reliable method of contraception. These subjects may be enrolled at the Investigator's discretion if they are counseled to remain sexually inactive during the study and understand the possible risks in getting pregnant during the study.

ii. Facial acne IGA score of 3 or 4.

iii. Able to understand the requirements of the study and sign /HIPAA Authorization forms. Subjects under the legal age of consent in the state where the study is conducted must also have the written, informed consent of a parent or legal guardian.

Exclusion criteria

Exclusion Criteria:

i. Female subjects who are pregnant (positive urine pregnancy test), breast-feeding, or who are of and not practicing a reliable method of .

ii. Allergy or sensitivity to any component of the test medications. iii. Subjects who have not complied with the proper for prohibited medications .

iv. Medical condition that, in the opinion of the Investigator, contraindicates the subject's participation in the clinical study.

v. Skin disease/disorder that might interfere with the diagnosis or evaluation of acne vulgaris vi. Evidence of recent alcohol or drug abuse. vii. History of poor cooperation, non-compliance with medical treatment, or unreliability.

viii. Exposure to an drug study within 30 days of the Baseline Visit.

ix. Patients who have demonstrated (e.g., anaphylaxis) to clindamycin, benzoyl peroxide, any components of the formulation, or lincomycin. (4) • Patients with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis (including pseudomembranous colitis)

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Winlevi (clascoterone) 1% & Duac gel

    Drug: Winlevi (clascoterone) 1% & Duac gel

Interventions

06

What researchers measure

Primary outcomes

  1. The Primary Endpoint of This Study is the Percent of Patients Who Achieve Clear or Almost Clear on Investigator Global Assessment (IGA) Scale at Week 16.

    The investigator will evaluate global acne severity using the Investigator Global Assessment scale, which ranges from 0 to 5, where 0 represents clear skin and 5 represents very severe acne

    Time frame: Week 16

Secondary outcomes

  1. Percent of Total Lesion Reduction at Week 16 Compared to Baseline

    Time frame: Week 16

  2. Percent of Inflammatory Lesion Reduction at Week 16 Compared to Baseline

    Time frame: Week 16

  3. Percent of Non-inflammatory Lesion Reduction at Week 16 Compared to Baseline.

    Time frame: Week 16

  4. Tolerability Measures of Erythema Based on 5-point Severity Scale

    The score in the scale ranges from 0-4. Lower score represents absence of erythema and higher score represents severe condition. The information presented represents the "Percentage of participant" with "Absent or Trace" erythema at weeks 4,8,12 and 16

    Time frame: Week 4,8,12,16

  5. Tolerability Measures of Dryness Based on 5-point Severity Scale

    The score in the scale ranges from 0-4. Lower score represents absence of dryness and higher score represents severe condition. The information presented represents the "Percentage of participant" with "Absent or Trace" dryness at weeks 4,8,12 and 16.

    Time frame: Week 4,8,12,16

  6. Tolerability Measures of Peeling Based on 5-point Severity Scale

    The score in the scale ranges from 0-4. Score 0 represents absence of peeling and Score 4 represents 'Extensive peeling'. The information presented represents the "Percentage of participant" with "Absent or Trace" peeling at weeks 4,8,12 and 16

    Time frame: Week 4,8,12,16

  7. Assessment of Skin Oiliness Based on 5-point Severity Scale

    The score in the scale ranges from 0-4. Score 0 represents absence of Oiliness and Score 4 represents severe condition. The information presented represents the "Percentage of participant" with "Absent or Trace" oiliness at weeks 4,8,12 and 16

    Time frame: Week 4,8,12,16

  8. Tolerability Measures of Burning/Stinging Based on 6-point Severity Scale

    The score in the scale ranges from 0-5. Lower score represents absence of discomfort and higher score represents severe condition. The information presented represents the "Percentage of participant" with "Absent or Trace" burning at weeks 4,8,12 and 16

    Time frame: Week 4,8,12,16

  9. Tolerability Measures of Pruritus Based on 6-point Severity Scale

    The score in the scale ranges from 0-5. Lower score represents absence of discomfort and higher score represents severe condition. The information presented represents the "Percentage of participant" with "Absent or Trace" Pruritus at weeks 4,8,12 and 16

    Time frame: Week 4,8,12,16

07

Results

Posted Jul 17, 2025

Participant flow

Participant flow — Overall Study
MilestoneWinlevi (Clascoterone) 1% & Duac Gel
Started10
Completed9
Not completed1

Outcome measures

PrimaryThe Primary Endpoint of This Study is the Percent of Patients Who Achieve Clear or Almost Clear on Investigator Global Assessment (IGA) Scale at Week 16.

The investigator will evaluate global acne severity using the Investigator Global Assessment scale, which ranges from 0 to 5, where 0 represents clear skin and 5 represents very severe acne

Time frame:
Week 16
Reported as:
Number · Percentage of patients
The Primary Endpoint of This Study is the Percent of Patients Who Achieve Clear or Almost Clear on Investigator Global Assessment (IGA) Scale at Week 16.
Percentage of patientsWinlevi (Clascoterone) 1% & Duac Gel
The Primary Endpoint of This Study is the Percent of Patients Who Achieve Clear or Almost Clear on Investigator Global Assessment (IGA) Scale at Week 16.100
Statistical analysis
  • Winlevi (Clascoterone) 1% & Duac Gel · Two-sided: 100
SecondaryPercent of Total Lesion Reduction at Week 16 Compared to Baseline
Time frame:
Week 16
Reported as:
Mean · Percent change
Percent of Total Lesion Reduction at Week 16 Compared to Baseline
Percent changeWinlevi (Clascoterone) 1% & Duac Gel
Percent of Total Lesion Reduction at Week 16 Compared to Baseline92 ± 8.2
Statistical analysis
  • Winlevi (Clascoterone) 1% & Duac Gel · Wilcoxon (Mann-Whitney) · p = 0.008
SecondaryPercent of Inflammatory Lesion Reduction at Week 16 Compared to Baseline
Time frame:
Week 16
Reported as:
Mean · Percent change
Percent of Inflammatory Lesion Reduction at Week 16 Compared to Baseline
Percent changeWinlevi (Clascoterone) 1% & Duac Gel
Percent of Inflammatory Lesion Reduction at Week 16 Compared to Baseline96.4 ± 6
Statistical analysis
  • Winlevi (Clascoterone) 1% & Duac Gel · Wilcoxon rank-sum test · p = 0.007
SecondaryPercent of Non-inflammatory Lesion Reduction at Week 16 Compared to Baseline.
Time frame:
Week 16
Reported as:
Mean · Percent change
Percent of Non-inflammatory Lesion Reduction at Week 16 Compared to Baseline.
Percent changeWinlevi (Clascoterone) 1% & Duac Gel
Percent of Non-inflammatory Lesion Reduction at Week 16 Compared to Baseline.86.1 ± 15.3
Statistical analysis
  • Winlevi (Clascoterone) 1% & Duac Gel · Wilcoxon rank sum test · p = 0.009
SecondaryTolerability Measures of Erythema Based on 5-point Severity Scale

The score in the scale ranges from 0-4. Lower score represents absence of erythema and higher score represents severe condition. The information presented represents the "Percentage of participant" with "Absent or Trace" erythema at weeks 4,8,12 and 16

Time frame:
Week 4,8,12,16
Reported as:
Number · Percentage of participant
Tolerability Measures of Erythema Based on 5-point Severity Scale
Percentage of participantWinlevi (Clascoterone) 1% & Duac Gel
Baseline66 (31 to 91)
Week 488 (51 to 99)
Week 888 (51 to 99)
Week 1288 (51 to 99)
Week 16100 (63 to 100)
Statistical analysis
  • Winlevi (Clascoterone) 1% & Duac Gel · Wilcoxon signed rank · p = 0.037 (P-value from Baseline at Week 16)P-value from Baseline at Week 16
SecondaryTolerability Measures of Dryness Based on 5-point Severity Scale

The score in the scale ranges from 0-4. Lower score represents absence of dryness and higher score represents severe condition. The information presented represents the "Percentage of participant" with "Absent or Trace" dryness at weeks 4,8,12 and 16.

Time frame:
Week 4,8,12,16
Reported as:
Number · Percentage of participant
Tolerability Measures of Dryness Based on 5-point Severity Scale
Percentage of participantWinlevi (Clascoterone) 1% & Duac Gel
Baseline100 (63 to 100)
Week 4100 (63 to 100)
Week 8100 (63 to 100)
Week 12100 (63 to 100)
Week 16100 (63 to 100)
SecondaryTolerability Measures of Peeling Based on 5-point Severity Scale

The score in the scale ranges from 0-4. Score 0 represents absence of peeling and Score 4 represents 'Extensive peeling'. The information presented represents the "Percentage of participant" with "Absent or Trace" peeling at weeks 4,8,12 and 16

Time frame:
Week 4,8,12,16
Reported as:
Number · percentage of participants
Tolerability Measures of Peeling Based on 5-point Severity Scale
percentage of participantsWinlevi (Clascoterone) 1% & Duac Gel
Baseline100 (63 to 100)
Week 4100 (63 to 100)
Week 8100 (63 to 100)
Week 12100 (63 to 100)
Week 16100 (63 to 100)
Statistical analysis
  • Winlevi (Clascoterone) 1% & Duac Gel · Wilcoxon signed rank · p = 1 (P-value from Baseline at Week 16)
SecondaryAssessment of Skin Oiliness Based on 5-point Severity Scale

The score in the scale ranges from 0-4. Score 0 represents absence of Oiliness and Score 4 represents severe condition. The information presented represents the "Percentage of participant" with "Absent or Trace" oiliness at weeks 4,8,12 and 16

Time frame:
Week 4,8,12,16
Reported as:
Number · percentage of participants
Assessment of Skin Oiliness Based on 5-point Severity Scale
percentage of participantsWinlevi (Clascoterone) 1% & Duac Gel
Baseline100 (63 to 100)
Week 4100 (63 to 100)
Week 8100 (63 to 100)
Week 12100 (63 to 100)
Week 16100 (63 to 100)
Statistical analysis
  • Winlevi (Clascoterone) 1% & Duac Gel · Wilcoxon signed rank · p = 1 (P-value from Baseline at Week 16)
SecondaryTolerability Measures of Burning/Stinging Based on 6-point Severity Scale

The score in the scale ranges from 0-5. Lower score represents absence of discomfort and higher score represents severe condition. The information presented represents the "Percentage of participant" with "Absent or Trace" burning at weeks 4,8,12 and 16

Time frame:
Week 4,8,12,16
Reported as:
Number · percentage of participants
Tolerability Measures of Burning/Stinging Based on 6-point Severity Scale
percentage of participantsWinlevi (Clascoterone) 1% & Duac Gel
Baseline100 (63 to 100)
Week 4100 (63 to 100)
Week 888 (51 to 99)
Week 12100 (63 to 100)
Week 16100 (63 to 100)
SecondaryTolerability Measures of Pruritus Based on 6-point Severity Scale

The score in the scale ranges from 0-5. Lower score represents absence of discomfort and higher score represents severe condition. The information presented represents the "Percentage of participant" with "Absent or Trace" Pruritus at weeks 4,8,12 and 16

Time frame:
Week 4,8,12,16
Reported as:
Number · percentage of partiicipants
Tolerability Measures of Pruritus Based on 6-point Severity Scale
percentage of partiicipantsWinlevi (Clascoterone) 1% & Duac Gel
Baseline100 (63 to 100)
Week 4100 (63 to 100)
Week 8100 (63 to 100)
Week 1288 (51 to 99)
Week 16100 (63 to 100)

Adverse events

Collected over 16 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Winlevi (Clascoterone) 1% & Duac Gel0/9 (0%)0/9 (0%)0/9 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Winlevi (Clascoterone) 1% & Duac Gel
Mean33 ± 17
Sex: Female, Male
Sex: Female, Male(Participants)Winlevi (Clascoterone) 1% & Duac Gel
Female5
Male4
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Winlevi (Clascoterone) 1% & Duac Gel
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American4
White5
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Skin Sciences, PLLC
    Louisville, Kentucky 40217, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Jul 2024, 7 months.

Results were first posted in Jul 2025, 1 year after primary completion.

Of 45 phase 4 interventional studies under Acne Vulgaris, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2024
First posted
Mar 29, 2024
StartActual
Nov 15, 2023
Primary completionActual
Jul 10, 2024
CompletionActual
Jul 10, 2024
Results first posted
Jul 17, 2025
Last update
Jul 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06336629
Responsible party
Sponsor
First posted
Mar 29, 2024
Start date
Nov 15, 2023
Primary completion
Jul 10, 2024
Completion
Jul 10, 2024
Results posted
Jul 17, 2025
Last update
Jul 17, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clascoterone

Start the discussion